Autologous Plasmablasts not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.”In the company’s words, NCT05682144 on ClinicalTrials.gov
- Tested for
- Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS
- Main trialPhase 1
- “A first-in-human study using ISP-001 in patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.”In the company’s words, NCT05682144 on ClinicalTrials.gov
Coming up1
- 1 Jun 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Jun 2029 | ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026